Table 2.

Superiority of carboplatin-contain-ing regimens in the neoadjuvant setting [1]

Author [ref.]	Study	Regimen	pCR rate
Sikov WM et al. [22]	CALGB 40603 phase II	paclitaxel 80mg/m2 qw ×12 + Cb AUC 6 q3w ×4 – dd AC q2w ×4	TNBC ± Cb: 54 vs. 41% (ypT0/is ypN0)
Von Minckwitz G et al. [23]	GeparSixto phase II	NPLD 20 mg/m2 qw ×18 + paclitaxel 80 mg/m2 qw ×18 + Cb AUC 1.5 qw ×18 + Bev 15 mg/kg q3w ×6	TNBC ± Cb: 53 vs. 37% (ypT0 ypN0)
Ando M et al. [24]	phase II	paclitaxel 80 mg/m2 qw ×12 + Cb AUC 5 q3w ×4 – FEC q3w ×4	TNBC ± Cb: 61 vs. 26%

pCR = Pathologic complete remission; AUC = area under the curve; dd = dose-dense; AC = adriamycin, cyclophosphamide; NPLD = non-pegylated doxorubicin; TNBC = triple-negative breast cancer; Cb = carboplatin; Bev = bevacizumab; qw = weekly; q2w = every 2 weeks; q3w = every 3 weeks; FEC = 5-fluorouracil, epirubicin, cyclophosphamide; CALGB = Cancer and Leukemia Group B.